Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study

Helen Lee¹, Nabeel Khan^{1

2}

Affiliations

¹ Department of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.

Editorial

Helen Lee et al. Aliment Pharmacol Ther. 2022 Aug.

. 2022 Aug;56(4):731-732.

doi: 10.1111/apt.16957.

Helen Lee¹, Nabeel Khan^{1

2}

¹ Department of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.

No abstract available

Comment in

Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.
Pugliese D, Privitera G, Armuzzi A. Pugliese D, et al. Aliment Pharmacol Ther. 2022 Aug;56(4):733-734. doi: 10.1111/apt.17076. Aliment Pharmacol Ther. 2022. PMID: 35879901 No abstract available.

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A; IG‐IBD LIVE Study Group. Pugliese D, et al. Aliment Pharmacol Ther. 2022 Jul;56(1):95-109. doi: 10.1111/apt.16923. Epub 2022 May 12. Aliment Pharmacol Ther. 2022. PMID: 35876062 Free PMC article.

1. van Marum RJ. Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol. 2020;86:2014-6. https://doi.org/10.1111/bcp.14539
1. Jeuring SFG, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-Camps MJL, Oostenbrug LE, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis. 2016;22(6):1425-34. https://doi.org/10.1097/MIB.0000000000000738
1. Feagan BG, Rutgeerts P, Sands BF, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
1. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21.
1. Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn's disease patients stratified by age. Adv Ther. 2017;34:542-59.